Clinicians often face uncertainty when managing mild respiratory failure related to COVID-19. While the original COVID-HIGH trial showed no statistical significance, researchers recently performed a Bayesian reanalysis. This specific study evaluates high-flow nasal therapy COVID-19 versus conventional oxygen therapy (COT). The results suggest a high probability of benefit for patients receiving HFNT.

Predicting Respiratory Support Escalation

Specifically, the primary outcome focused on the escalation of respiratory support within 28 days. In the HFNT group, 23.6% of patients required escalation, compared to 30.2% in the COT group. Although the initial frequentist p-value was 0.14, the Bayesian model showed a high probability of benefit. Furthermore, the posterior probability of a positive outcome ranged between 70% and 94% across various models. The proportion of patients facing potential harm remained consistently low at less than 6%.

Optimizing High-flow Nasal Therapy COVID-19 Usage

In addition, clinical recovery at day 14 was significantly improved in the HFNT group. Consequently, 61.5% of the HFNT group recovered compared to 53.3% of the COT group. This leads to a posterior probability of clinical benefit between 61% and 73%. Moreover, the Bayesian approach provides a more intuitive quantification of uncertainty. Therefore, these findings suggest that high-flow nasal therapy COVID-19 likely reduces treatment escalation. Doctors should consider these probabilities when determining the best course for mild hypoxaemia.

Frequently Asked Questions

Is high-flow nasal therapy better than conventional oxygen for mild COVID-19?

According to the Bayesian reanalysis, high-flow nasal therapy COVID-19 has a 70% to 94% probability of reducing the need for escalated respiratory support compared to conventional oxygen therapy.

What was the clinical recovery rate in the COVID-HIGH trial?

The HFNT group showed a recovery rate of 61.5% at day 14, while the COT group showed 53.3%. This suggests a significant probability of clinical benefit for those using HFNT.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Crimi C et al. High-flow nasal therapy vs conventional oxygen therapy in mild COVID-19 hypoxaemia: a Bayesian reanalysis of the COVID-HIGH Trial. J Anesth Analg Crit Care. 2026 Feb 21. doi: 10.1186/s44158-026-00361-3. PMID: 41723547.

Crimi C, Noto A, Madotto F, et al. High-flow nasal oxygen versus conventional oxygen therapy in patients with COVID-19 pneumonia and mild hypoxaemia: a randomised controlled trial. Thorax. 2023;78(4):354-361. doi: 10.1136/thoraxjnl-2022-218806.

Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022;327(6):546–558. doi: 10.1001/jama.2022.0028.